Product Description
Mechanisms of Action: nAChR Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Institute on Drug Abuse (NIDA)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Chronic Pain|Acute Pain
Phase 2: Tobacco Use Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07003282 |
First Breath | N/A |
Recruiting |
Pregnancy Outcomes|Tobacco Use Disorder |
2025-10-30 |
2025-09-13 |
Primary Endpoints |
|
NCT06645340 |
PRE_Smoking | N/A |
Completed |
Pre-Eclampsia|Hypertension, Pregnancy-Induced|Pregnancy Outcomes |
2022-09-30 |
2024-10-24 |
||
NCT02897401 |
CANICE | N/A |
Unknown status |
Tobacco Use Disorder|Carcinogenesis |
2017-11-01 |
2024-12-19 |
Primary Endpoints|Treatments |
|
NCT03062709 |
NCT03062709 | N/A |
Completed |
Asthma|Tobacco Use Disorder|Pneumonia|Bronchiolitis|Smoking Cessation|Bronchopulmonary Dysplasia |
2017-03-30 |
2021-04-27 |
Primary Endpoints|Treatments |
|
NCT00217893 |
R01HL066307 | N/A |
Completed |
Asthma |
2008-01-01 |
2019-03-21 |
Treatments |
|
ACTRN12612000399897 |
ENtiCe | N/A |
Not yet recruiting |
Pregnancy Outcomes|Tobacco Use Disorder |
None |
2024-04-03 |
Treatments |
|
NCT01828502 |
SCUSF 1201 | P2 |
Withdrawn |
Tobacco Use Disorder |
2016-06-01 |
2019-03-19 |
Treatments |
|
NCT00000284 |
NIDA-09259-1 | P2 |
Completed |
Tobacco Use Disorder |
None |
2019-03-21 |
Treatments |
|
NCT00000288 |
NIDA-09259-5 | P2 |
Completed |
Tobacco Use Disorder |
None |
2019-03-21 |
Treatments |
|
NCT00000296 |
NIDA-09259-13 | P2 |
Completed |
Tobacco Use Disorder |
None |
2019-03-21 |
Treatments |
|
NCT04274673 |
NCT04274673 | P4 |
Unknown status |
Chronic Pain|Acute Pain |
2020-05-13 |
2022-02-02 |
Primary Endpoints|Treatments|Trial Status |